These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9695208)

  • 1. The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy.
    Rusthoven JJ; Osoba D; Butts CA; Yelle L; Findlay H; Grenville A
    Support Care Cancer; 1998 Jul; 6(4):389-95. PubMed ID: 9695208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
    Osoba D; Zee B; Pater J; Warr D; Latreille J; Kaizer L
    J Clin Oncol; 1997 Jan; 15(1):116-23. PubMed ID: 8996132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
    Osoba D; Zee B; Warr D; Latreille J; Kaizer L; Pater J
    Support Care Cancer; 1997 Jul; 5(4):307-13. PubMed ID: 9257427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting.
    Jordan K; Grothey A; Pelz T; Lautenschläger C; Franke U; Schöber C; Schmoll HJ
    Eur J Cancer Care (Engl); 2010 Sep; 19(5):603-9. PubMed ID: 19725867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
    Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
    Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.
    Glaus A; Knipping C; Morant R; Böhme C; Lebert B; Beldermann F; Glawogger B; Ortega PF; Hüsler A; Deuson R
    Support Care Cancer; 2004 Oct; 12(10):708-15. PubMed ID: 15278682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of concord grape juice on chemotherapy-induced nausea and vomiting: results of a pilot study.
    Ingersoll GL; Wasilewski A; Haller M; Pandya K; Bennett J; He H; Hoffmire C; Berry C
    Oncol Nurs Forum; 2010 Mar; 37(2):213-21. PubMed ID: 20189927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring chemotherapy-induced nausea and emesis.
    Martin CG; Rubenstein EB; Elting LS; Kim YJ; Osoba D
    Cancer; 2003 Aug; 98(3):645-55. PubMed ID: 12879484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.
    Decker GM; DeMeyer ES; Kisko DL
    J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
    Kaizer L; Warr D; Hoskins P; Latreille J; Lofters W; Yau J; Palmer M; Zee B; Levy M; Pater J
    J Clin Oncol; 1994 May; 12(5):1050-7. PubMed ID: 8164029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.
    Ballatori E; Roila F
    Health Qual Life Outcomes; 2003 Sep; 1():46. PubMed ID: 14521717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC).
    Schwartzberg L; Szabo S; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
    Curr Med Res Opin; 2011 Apr; 27(4):837-45. PubMed ID: 21309647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy].
    Gozzo Tde O; Moysés AM; da Silva PR; de Almeida AM
    Rev Gaucha Enferm; 2013 Sep; 34(3):110-6. PubMed ID: 24344592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
    Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.